Mindray to acquire HyTest from Summa Equity for $665m.

Mindray, a company that develops, manufactures, and markets medical devices, agreed to acquire HyTest, a manufacturer of scientifically created antibodies, from Summa Equity, a thematic investment companyб for $665m. "With the resources available from Mindray, we can further develop our capabilities to serve our customers and fulfill their needs for best-in-class reagents for developing reliable and sensitive immunoassays on various platforms," Juhana Rauramo, HyTest CEO.